首页> 外文期刊>Cell death and differentiation >CD147 induces UPR to inhibit apoptosis and chemosensitivity by increasing the transcription of Bip in hepatocellular carcinoma.
【24h】

CD147 induces UPR to inhibit apoptosis and chemosensitivity by increasing the transcription of Bip in hepatocellular carcinoma.

机译:CD147诱导UPR通过增加肝细胞癌的BIP转录来抑制凋亡和化学敏感性。

获取原文
获取原文并翻译 | 示例
           

摘要

The unfolded protein response (UPR) is generally activated in solid tumors and results in tumor cell anti-apoptosis and drug resistance. However, tumor-specific UPR transducers are largely unknown. In the present study, we identified CD147, a cancer biomarker, as an UPR inducer in hepatocellular carcinoma (HCC). The expression of the major UPR target, Bip, was found to be positively associated with CD147 in human hepatoma tissues. By phosphorylating FAK and Src, CD147-enhanced TFII-I tyrosine phosphorylation at Tyr248. CD147 also induced p-TFII-I nuclear localization and binding to the Bip promoter where endoplasmic reticulum (ER) stress response element 1 (ERSE1) (-82/-50) is the most efficient target of the three ERSEs, thus increasing transcription of Bip. Furthermore, by inducing UPR, CD147 inhibited HCC cell apoptosis and decreased cell Adriamycin chemosensitivity, thus decreasing the survival rate of hepatoma-bearing nude mice. Together, these results reveal pivotal roles for CD147 in modulating the UPR in HCC and raise the possibility that CD147 is a target that promotes HCC cell apoptosis and increases the sensitivity of tumors to anti-cancer drugs. Therefore, CD147 inhibition provides an opportunity to enhance the efficacy of existing agents and represents a novel target for HCC treatment.
机译:展开的蛋白质反应(UPR)通常在实体肿瘤中激活并导致肿瘤细胞抗凋亡和耐药性。然而,肿瘤特异性UPR换能器在很大程度上是未知的。在本研究中,我们鉴定了CD147,癌症生物标志物,作为肝细胞癌(HCC)中的UPR诱导剂。发现主要uPR靶标的表达BIP与人肝癌组织中的CD147正面相关。通过磷酸化FAK和SRC,CD147增强的TFII-I酪氨酸磷酸化在TYR248。 CD147还诱导P-TFII-I核定位并结合到BIP启动子,其中内质网(ER)应激响应元件1(ERS1)(-82 / -50)是三个eRSE的最有效的靶标,从而增加转录BIP。此外,通过诱导UPR,CD147抑制HCC细胞凋亡并降低细胞adriamcin化学敏感性,从而降低了患肝癌的裸鼠的存活率。这些结果揭示了CD147在调节HCC中调节UPR的枢轴作用,并提高CD147是促进HCC细胞凋亡的靶标的可能性,并增加肿瘤对抗癌药物的敏感性。因此,CD147抑制提供了增强现有药物功效并代表HCC治疗的新靶标的机会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号